FUJIFILM Holdings (FUJIY) trades at a forward enterprise value/EBITDA multiple of approximately 8.5x, below its five-year average of 9.2x, reflecting conservative market sentiment despite the company’s stable earnings. Its four core segments—Healthcare (30% of sales), Electronics (25%), Business Innovation (20%) and Imaging (25%)—contribute diversified cash flows. Healthcare revenues grew 7% year-over-year in FY2025, driven by expanded oncology diagnostic reagents, while its advanced semiconductor materials business in Electronics posted 12% sales growth, reflecting strong orders from leading chip manufacturers investing in AI infrastructure.

FUJIY’s balance sheet shows total debt of ¥1.02 trillion against cash and equivalents of ¥680 billion, resulting in net debt of ¥340 billion. Despite leverage, the company maintained a stable interest coverage ratio of 12x in FY2025, supported by operating cash flow of ¥270 billion. Adjusted operating margin improved to 14.8%, up from 14.1% the prior year, driven by cost efficiencies in its digital printing business and higher-margin medical imaging consumables. Analysts have revised full-year EPS estimates upward by an average of 4.5% over the past three months.

The Japanese yen depreciated roughly 6% against the US dollar over the past year, enhancing FUJIY’s overseas profit conversion. With overseas sales representing 55% of revenue, the currency shift is expected to add approximately ¥15 billion to annual operating profit. Management reiterated its FY2026 guidance for mid-single-digit revenue growth and an operating margin target of 15.5%, citing planned capital investments of ¥120 billion in R&D and production capacity for next-generation bio-pharmaceuticals and specialty optical films used in AI-driven sensor applications.